Key result
Once-daily netarsudil matches twice-daily timolol for lowering intraocular pressure in patients with baseline IOP <25 mmHg.
Why the study?
Netarsudil ophthalmic solution 0.02% is approved for lowering elevated IOP in open-angle glaucoma or ocular hypertension, but comprehensive clinical data summaries are needed.
Answers are grounded in this paper and cite their sources.
Supports once-daily netarsudil as convenient alternative to twice-daily timolol for IOP control; confirms ROCK inhibitor efficacy in open-angle glaucoma.
Once-daily (p.m.) netarsudil ophthalmic solution 0.02% (Rhopressa) is approved in the United States for lowering elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Netarsudil, a Rho kinase (ROCK) inhibitor that lowers IOP primarily by increasing trabecular outflow, produces statistically and clinically significant reductions in mean IOP from baseline, with comparable effects on nocturnal and diurnal IOP. In three phase III trials of patients with elevated IOP, the ocular hypotensive efficacy of once-daily netarsudil 0.02% met the criteria for noninferiority to twice-daily timolol 0.5% at all time points over 3 months in patients with baseline IOP less than 25 mmHg. The most frequent adverse event (AE) was generally mild conjunctival hyperemia, the severity of which did not increase with continued dosing. Netarsudil was associated with minimal treatment-related serious or systemic AEs, likely due to the lack of systemic exposure. This report summarizes the available preclinical and clinical data on netarsudil.
No takes yet. Share an insight, caveat, or question.
Kopczynski et al. (2018) conducted a review in Open-angle glaucoma or ocular hypertension. Netarsudil ophthalmic solution vs. Timolol 0.5% twice-daily was evaluated on Reduction in intraocular pressure (IOP). Once-daily netarsudil 0.02% met criteria for noninferiority to twice-daily timolol 0.5% in lowering intraocular pressure at all time points over 3 months in patients with baseline IOP less than 25 mmHg.
Synapse has enriched 10 related papers. Consider them for comparative context: